Member Info for Energyshares

One of my favourite stories,Hare races ahead bubble bursts and the tortoise with his superior affimers wins the race. :)

Lol sorry Matt

Just realised with the ADC Therapeutics deal. Switzerland and now Covid test validation in a European hospital.

Avacta have been to Europe more than Everton in the last year.

It looks like Mologic have conceded that Avacta’s affimers must be superior to their test otherwise they wouldn’t release manufacturing capacity to Avacta.

But have Mologic played a blinder....
From this weeks RNS

The partnership between Avacta and Mologic also provides a framework agreement for the future development of a pipeline of tests in a range of disease areas. The possibility of combining Avacta's spike antigen test with Mologic's nucleocapsid antigen-based technology[2] in a single lateral flow device is already being explored. A hybrid antigen test such as this is expected to be a world first and has the potential to deliver an extremely sensitive lateral flow coronavirus antigen test.

Before Covid came along the global market for lateral flow disease testing is estimated to reach $17.5 billion by 2027, growing at a CAGR of 5.7% over the forecast period, driven by discovery of new drug resistant pathogens, increasing demand for point-of-care diagnostics, and rapidly increasing healthcare costs.

Lateral flow technology is frequently used for the diagnosis of the following targets, amongst many other targets:
* Malaria.
* Dengue.
* Influenza A and B.
* HIV.
* Chlamydia.
* Hepatitis.
* Tuberculosis (TB)
* Epstein Barr virus (EBV)
* Cardiac Marker Lipid Test.

Now have Mologic spotted that Avacta affimers and their CARD technology can take a large slice of the above markets & Covid market.

Mologic established the Centre for Advanced Rapid diagnostics (CARD). The programme is designed to develop a new, ultra-sensitive technology platform testing the limits of rapid diagnostic performance.

Mark Davis, Chief Executive Officer of Mologic, said: "Mologic offers a highly versatile range of scientific and manufacturing services for the development of diagnostic technology. We are very pleased to be working with Avacta to apply our expertise in this important project and look forward to it paving the way for further collaborations."

https://www.ihealthcareanalyst.com/lateral-flow-disease-testing-market-2020-increased-drug-resistant-pathogens/amp/

This time next year Del

Affimer Ltd sitting dormant since 2013
Is this a spin off in the future ?
https://find-and-update.company-information.service.gov.uk/company/08458974/filing-history

MB reminds me of Hamburgler from McDonalds advert :)

The 2 companies who ran with saliva,
Avacta & Mologic form a collaboration after it looked liked they both ditched saliva.

The only way to roll out billions of tests to the under developed world is cheap spit sticks.
Spitfire MK 2

23rd November
significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test.
Next
21st December
In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon.

This week
to accelerate to market Avacta's AffiDX™ SARS-CoV-2 lateral flow rapid antigen test.

This is the first time Avacta have named their Test.

If you remember last year we were in a race with Mologic for the first saliva test . Avacta have seemed to drop saliva and Mologic also dropped saliva and gone to a swab.

The Big Question why would Mologic help us out.

Remember Mologic rushing a small batch to Porton Down in January, could they be using Affimers on their new test and in exchange helping Avacta over the line.

Also third world countries won’t be able to source all the components in the tests available now and ship and keep margins down.

So this new Test with Mologic will be Saliva, these countries won’t be worrying about anyone eating a Burger, before taking the test and all the other stupid health & safety that the developed world has in place.

Take a look at Mologic remit from Gates foundation:
https://mologic.co.uk/case-studies/the-centre-for-advanced-rapid-diagnostics-card/

Saliva will probably work that well and be so cheap that the developed world will probably start using it.

Hp420
Remember Avacta retweeting this 11/11/20
https://www.bloomberg.com/news/articles/2020-11-11/heathrow-ceo-says-covid-tests-needed-for-years-even-with-vaccine

It’s a swab brain tickler very uncomfortable.
£15 each box of 20. £300

https://www.bivda.org.uk/The-IVD-Industry/Find-a-Member/Member-Press-Releases/ArticleID/142/Mologic-receives-a-4-8m-grant-to-establish-the-centre-for-advanced-rapid-diagnostics-card

Big Al has used their title in our RNS
:):):):)
Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries

Gates just give a grant to Mologic to develop a test.

First $120 million in the bag.
https://www.who.int/news/item/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low--and-middle-income-countries

Milk 1 sugar :)

Government want to make a sovereign best in class LFT.
Abingdon and BBI can produce 12m of Avacta’s Holy Grail tests.

What is Omega using as their reagents it’s got to be the same as Abingdon and BBI or they are going to have a holy grail test and a inferior test.

So we have until 2033 to maximise affimer potential for diagnostics and Therapeutic sides of the business.

Affimer patent granted 2013 UK
2014 USA
2018 China

Generally, the term of a new patent is 20 years from the date on which the application for the patent was filed in the UK or United States,EU,China,Russia.

Antibody test catch up.....

Captain Stanley
When he turns up at the party.
https://m.youtube.com/watch?v=4trn2lJxl00